352 related articles for article (PubMed ID: 20049969)
1. The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
Rakha EA; Patil S; Abdulla K; Abdulkader M; Chaudry Z; Soomro IN
Diagn Cytopathol; 2010 Dec; 38(12):874-9. PubMed ID: 20049969
[TBL] [Abstract][Full Text] [Related]
2. Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma.
Sherman ME; Mark EJ
Arch Pathol Lab Med; 1990 Aug; 114(8):845-51. PubMed ID: 2375659
[TBL] [Abstract][Full Text] [Related]
3. Cytologic re-evaluation of negative effusions from patients with malignant mesothelioma.
Ascoli V; Bosco D; Carnovale Scalzo C
Pathologica; 2011 Dec; 103(6):318-24. PubMed ID: 22558888
[TBL] [Abstract][Full Text] [Related]
4. The role of cytological evaluation of pleural fluid in diagnosing malignant mesothelioma.
Lovrenski A; Panjković M; Tegeltija D; Latinović LT; Krcedinac J
Med Pregl; 2012; 65(1-2):5-8. PubMed ID: 22452231
[TBL] [Abstract][Full Text] [Related]
5. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
6. The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey.
Paintal A; Raparia K; Zakowski MF; Nayar R
Cancer Cytopathol; 2013 Dec; 121(12):703-7. PubMed ID: 24039177
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
[TBL] [Abstract][Full Text] [Related]
8. Image cytometry: an aid for cytological diagnosis of pleural effusions.
Osterheld MC; Liette C; Anca M
Diagn Cytopathol; 2005 Mar; 32(3):173-6. PubMed ID: 15690335
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic analysis of effusions from malignant mesothelioma. A diagnostic adjunct to cytology.
Granados R; Cibas ES; Fletcher JA
Acta Cytol; 1994; 38(5):711-7. PubMed ID: 8091903
[TBL] [Abstract][Full Text] [Related]
10. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic yield of pleural fluid cytology in malignant pleural effusions.
Ong KC; Indumathi V; Poh WT; Ong YY
Singapore Med J; 2000 Jan; 41(1):19-23. PubMed ID: 10783675
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic difficulties in pleural mesothelioma].
Dubaniewicz A; Siemińska A
Wiad Lek; 1992 Apr; 45(7-8):248-50. PubMed ID: 1462582
[TBL] [Abstract][Full Text] [Related]
13. A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit.
Segal A; Sterrett GF; Frost FA; Shilkin KB; Olsen NJ; Musk AW; Nowak AK; Robinson BW; Creaney J
Pathology; 2013 Jan; 45(1):44-8. PubMed ID: 23222247
[TBL] [Abstract][Full Text] [Related]
14. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.
Onofre FB; Onofre AS; Pomjanski N; Buckstegge B; Grote HJ; Böcking A
Cancer; 2008 Jun; 114(3):204-15. PubMed ID: 18306350
[TBL] [Abstract][Full Text] [Related]
15. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
Illei PB; Ladanyi M; Rusch VW; Zakowski MF
Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
[TBL] [Abstract][Full Text] [Related]
16. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis.
Cakir E; Demirag F; Aydin M; Unsal E
Diagn Cytopathol; 2009 Jan; 37(1):4-10. PubMed ID: 18973123
[TBL] [Abstract][Full Text] [Related]
17. The cytopathology of mesothelioma.
Tao LC
Acta Cytol; 1979; 23(3):209-13. PubMed ID: 294056
[TBL] [Abstract][Full Text] [Related]
18. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.
Matsumoto S; Nabeshima K; Kamei T; Hiroshima K; Kawahara K; Hata S; Marukawa K; Matsuno Y; Taguchi K; Tsujimura T
Cancer Cytopathol; 2013 Aug; 121(8):415-22. PubMed ID: 23450849
[TBL] [Abstract][Full Text] [Related]
19. The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy.
Kobzik L; Antman KH; Warhol MJ
Acta Cytol; 1985; 29(3):219-25. PubMed ID: 3859121
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.
Hiraki A; Aoe K; Murakami T; Nakamura Y; Yamazaki K; Sueoka N; Taguchi K; Kamei T; Maeda T; Takeyama H; Kishimoto T; Nishimura M; Sugi K
Oncol Rep; 2005 Aug; 14(2):357-62. PubMed ID: 16012715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
